Recombinant hIFN-gamma/Interferon-g |
|
Vaxjo ID |
54 |
|
Vaccine Adjuvant Name |
Recombinant hIFN-gamma/Interferon-g |
|
Alternative Names |
Actimmune® (rhIFN-gamma, Genentech, Inc.); immune interferon; IFN-g; gamma-interferon |
|
Adjuvant VO ID |
VO_0001296
|
|
Description |
Recombinant hIFN-gamma has been studied in humans as an adjuvant for Hepatitis B subunit antigen (Vogel and Powell, 1995). |
|
Stage of Development |
Clinical Trial |
|
Preparation |
Both human (rhIFN-gamma) and murine (rmuIFN-gamma) forms are expressed in Escherichia coli and distributed in a completely pure state (Vogel and Powell, 1995). |
|
Dosage |
Standard human dose is 100 μg (Vogel and Powell, 1995). |
|
Function |
Higher and earlier neutralizing antibody titers, increase in duration of neutralizing antibody titers, increase in MHC class 11 expression on antigen presenting cells, increase in Helper T cell levels, and an improved DTH response have all been observed when IFN-garnma was administered with an antigen. The IFN-gamma must be given at the same site and at the same time (within 6 hrs) as the antigen to have biological effect (Vogel and Powell, 1995). |
|
Safety |
rhIFN-gamma as Actimmune® is a FDA approved commercial product for human use. High doses can cause significant side effects such as nausea, fever, and other flu-like symptoms. Effect of molecule is specific to species. Human form does not elicit toxicity in lower species at several mg/kg doses which are toxic to humans (Vogel and Powell, 1995). |
| Related Vaccine(s) |
|
| References |
Vogel and Powell, 1995: Vogel FR, Powell MF. A compendium of vaccine adjuvants and excipients. Pharmaceutical biotechnology. 1995; 6; 141-228. [PubMed: 7551218].
|
